Page last updated: 2024-11-10

ag 331

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

AG 331: structure given in second source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9852216
SCHEMBL ID6760900
MeSH IDM0232341

Synonyms (19)

Synonym
157182-23-5
D04964
metesind glucuronate (usan)
metesind glucuronate
unii-8ec044476n
n(6)-(4-(n-morpholinosulfonyl)benzyl)-n(6)-methyl-2,6-diaminobenz(cd)indole glucuronate
8ec044476n ,
ag 331
ag331
metesind glucuronate [usan]
4-((alpha-((2-aminobenz(cd)indol-6-yl)methylamino)-p-tolyl)sulfonyl)morpholine mono-d-glucuronate
morpholine, 4-((4-(((2-aminobenz(cd)indol-6-yl)methylamino)methyl)phenyl)sulfonyl)-, mono-d-glucuronate
metesind glucuronate [who-dd]
4-((.alpha.-((2-aminobenz(cd)indol-6-yl)methylamino)-p-tolyl)sulfonyl)morpholine mono-d-glucuronate
SCHEMBL6760900
6-n-methyl-6-n-[(4-morpholin-4-ylsulfonylphenyl)methyl]benzo[cd]indole-2,6-diamine;(2s,3s,4s,5r)-2,3,4,5-tetrahydroxy-6-oxohexanoic acid
Q27270253
6-[n-methyl-n-[4-(morpholinosulfonyl)benzyl]amino]benz[cd]indol-2(1h)-imine glucuronate
AKOS040746104

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetics of the classical antifolate methotrexate have been well-defined and pharmacokinetic data can be exploited to reduce the toxicity and enhance the activity of the drug."( Clinical pharmacokinetics of antitumor antifolates.
Newell, DR, 1999
)
0.3

Dosage Studied

ExcerptRelevanceReference
" Upon achieving satisfactory pharmacologic parameters, the multiple dosing component (phase IB) was initiated."( Phase I study of AG 331, a novel thymidylate synthase inhibitor, in patients with refractory solid tumors.
Chatterjee, DJ; Clendinnin, N; Garcia, AA; Jeffers, S; Koda, RT; Leichman, CG; Leichman, L; Li, WY; Muggia, FM; Parimoo, D; Rogers, M; Shetty, BV; Webber, S; Wu, EY, 1999
)
0.3
" The mean terminal t1/2 following single doses was significantly shorter than the t1/2 following multiple dosing (6."( Phase I study of AG 331, a novel thymidylate synthase inhibitor, in patients with refractory solid tumors.
Chatterjee, DJ; Clendinnin, N; Garcia, AA; Jeffers, S; Koda, RT; Leichman, CG; Leichman, L; Li, WY; Muggia, FM; Parimoo, D; Rogers, M; Shetty, BV; Webber, S; Wu, EY, 1999
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's13 (86.67)18.2507
2000's2 (13.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (18.75%)5.53%
Reviews4 (25.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (56.25%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]